New MMR vaccine shows promise in protecting infants
NCT ID NCT06399003
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new measles, mumps, and rubella (MMR) vaccine made by Shanghai Institute of Biological Products in 1,200 healthy children aged 9-11 months. The goal was to see if it works as well as the licensed GSK MMR vaccine and is safe. Children received one dose, and researchers checked their immune response and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEASLES-MUMPS-RUBELLA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Victoria Biomedical Research Institute(VIBRI)
Kisumu, Kenya